PMID- 35726419
OWN - NLM
STAT- MEDLINE
DCOM- 20230208
LR  - 20240426
IS  - 2212-3989 (Electronic)
IS  - 1871-5265 (Print)
IS  - 1871-5265 (Linking)
VI  - 23
IP  - 1
DP  - 2023
TI  - MMP3 in Severe COVID-19: A Biomarker or Therapeutic Target?
PG  - e190622206159
LID - 10.2174/1871526522666220619121539 [doi]
AB  - Identifying novel therapies is a critical need in the treatment of coronavirus 
      disease-19 (COVID-19) and acute respiratory distress syndrome (ARDS). 
      Stromelysin-1, also known as matrixmetalloproteinase 3 (MMP3), has been 
      investigated as a diagnostic biomarker and a potential pharmacological target. 
      Here, we discuss the recent findings of Gelzo et al. in the context of additional 
      MMP3 investigations to delineate its exact role in diagnosis, prognostication, 
      and phenotyping, in addition to its promising role as a therapeutic target in 
      COVID-19-associated respiratory failure.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Almuntashiri, Sultan
AU  - Almuntashiri S
AD  - Clinical and Experimental Therapeutics, College of Pharmacy, University of 
      Georgia, Augusta, GA, 30912, USA.
FAU - Zhang, Duo
AU  - Zhang D
AD  - Clinical and Experimental Therapeutics, College of Pharmacy, University of 
      Georgia, Augusta, GA, 30912, USA.
FAU - Somanath, Payaningal R
AU  - Somanath PR
AD  - Clinical and Experimental Therapeutics, College of Pharmacy, University of 
      Georgia, Augusta, GA, 30912, USA.
FAU - Sikora, Andrea
AU  - Sikora A
AD  - Clinical and Experimental Therapeutics, College of Pharmacy, University of 
      Georgia, Augusta, GA, 30912, USA.
LA  - eng
GR  - KL2 TR002381/TR/NCATS NIH HHS/United States
GR  - UL1 TR002378/TR/NCATS NIH HHS/United States
PT  - Journal Article
PL  - United Arab Emirates
TA  - Infect Disord Drug Targets
JT  - Infectious disorders drug targets
JID - 101269158
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
RN  - 0 (Biomarkers)
RN  - EC 3.4.24.17 (MMP3 protein, human)
SB  - IM
CON - Infect Disord Drug Targets.
MH  - Humans
MH  - *COVID-19
MH  - Matrix Metalloproteinase 3/therapeutic use
MH  - *Respiratory Distress Syndrome/diagnosis/drug therapy
MH  - COVID-19 Drug Treatment
MH  - Biomarkers
PMC - PMC11042506
MID - NIHMS1931388
OTO - NOTNLM
OT  - ARDS
OT  - Biomarker
OT  - MMP3
OT  - potential pharmacological target
OT  - respiratory failure
OT  - therapeutic target
COIS- CONFLICT OF INTEREST The authors declare no conflict of interest, financial or 
      otherwise.
EDAT- 2022/06/22 06:00
MHDA- 2023/02/09 06:00
PMCR- 2024/04/24
CRDT- 2022/06/21 02:34
PHST- 2022/02/13 00:00 [received]
PHST- 2022/04/25 00:00 [revised]
PHST- 2022/04/29 00:00 [accepted]
PHST- 2022/06/22 06:00 [pubmed]
PHST- 2023/02/09 06:00 [medline]
PHST- 2022/06/21 02:34 [entrez]
PHST- 2024/04/24 00:00 [pmc-release]
AID - IDDT-EPUB-124610 [pii]
AID - 10.2174/1871526522666220619121539 [doi]
PST - ppublish
SO  - Infect Disord Drug Targets. 2023;23(1):e190622206159. doi: 
      10.2174/1871526522666220619121539.